AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04319900
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for favipiravir tablets is produced by Zhejiang Haizheng pharmaceutical co, LTD, batch no. 21812252, Placebo for chloroquine phosphate tablets is produced by the Chinese people's liberation army academy of military science military medical research institute production, batch no. 20200215. All placebos were complied with the quality inspection standard.
Trial: NCT02383810
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00398879
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 825 mg/m\^2 BID days 1 - 14 q 3 weeks
Trial: NCT00955526
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two placebo tablets once daily for 12 weeks
Trial: NCT01464606
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ≥ 3 year: 1.2 gm/m2/dose IV as 1 hr infusion with IV fluids
Trial: NCT01464606
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ≥ 3 years: 30 mg/m2/dose IV over 30 min, Days 1, 2 (60 mg/m2/cycle)
Trial: NCT04567433
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone compared to Placebo
Trial: NCT03021265
Drug: T80/A5/H12.5 FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug
Trial: NCT00541034
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05467436
Drug: Local anesthetics, IV sedation drugs and analgesics.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized prescription for local anesthetics, IV sedation drugs and analgesics, based on pharmacogenomic assesment, social, dietary and medication history
Trial: NCT03163550
Drug: ACHN-383
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose
Trial: NCT03163550
Drug: ACHN-789
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose
Trial: NCT03163550
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose
Trial: NCT05699720
Drug: Nebulized Magnesium Sulphate
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A received 250mg of MgSO4 /dose given through nebulizer four times a day, while group B did not. The groups will be followed for five days to see the results in terms of in-hospital outcome, whether the patient is discharged after fulfilling the set criteria or needing assisted ventilation.
Trial: NCT01656902
Drug: NOVOCART® 3D plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-Step intervention: 1) cartilage cells are collected from the patient during arthroscopy 2) collected cartilage cells are cultivated in a sterile environment, seeded in an organic matrix scaffold and implanted into the defect location (knee, femur)
Trial: NCT00665847
Drug: Optimized background regimen (OBR)
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An investigator-selected optimized background regimen (OBR) comprising of a low-dose ritonavir (rtv)-boosted protease inhibitor (PI) (either lopinavir \[LPV\], darunavir \[DRV\], atazanavir \[ATV\] or saquinavir \[SQV\]) in combination with nucleos(t)ide reverse transcriptase inhibitor(s) (N\[t\]RTIs) to be dosed according to the drugs individual package inserts for 48 weeks.
Trial: NCT04229615
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03965533
Drug: GSK2831781
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2831781 will be available as Dose-1 and Dose-2 as IV infusion or SC injection. Subjects will receive GSK2831781 Dose-1 IV diluted in 0.9% saline or GSK2831781 SC as multiples of Dose-2 SC.
Trial: NCT03965533
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be 0.9% saline solution which will be administered in subjects as IV infusion or SC injection.
Trial: NCT04234321
Drug: Kangfuxin Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kangfuxin Liquid,20ml / 100cm2 / time,three times a day.
Trial: NCT04234321
Drug: 0.9% Normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Normal saline,20ml / 100cm2 / time,three times a day.
Trial: NCT01590342
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac 75 mg, two doses
Trial: NCT01590342
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, two doses
Trial: NCT00975481
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet or capsule; placebo, single dose
Trial: NCT00324324
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin/Placebo 400 mg capsule orally once a day through D+100 after bone marrow transplant, then discontinue
Trial: NCT03447990
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Ascending Dose and Multiple Ascending Dose of placebo
Trial: NCT02022098
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo solution
Trial: NCT00616655
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo total daily dose 0.9 mg
Trial: NCT01863225
Drug: RVX000222
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 14-days
Trial: NCT01863225
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg daily, 28-42 days
Trial: NCT01863225
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mg daily, 28-42 days
Trial: NCT01551693
Drug: STA-9090
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00830336
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral Suspension
Trial: NCT00830336
Drug: Zithromax®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Suspension
Trial: NCT03984604
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is a vehicle oil will match CHI-921
Trial: NCT01920113
Drug: Dexmedetomidine - remifentanil group
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01920113
Drug: Propofol - remifentanil group
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01853280
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg matched placebo comparator, with open-label OROS-Methylphenidate
Trial: NCT00619918
Drug: Nebulized 3% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml inhaled q8h
Trial: NCT00619918
Drug: Nebulized 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline
Trial: NCT01066299
Drug: Syntocinon®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of OXT (24 IU)
Trial: NCT01472185
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match ranolazine administered orally twice daily.
Trial: NCT00764426
Drug: red wine, beer, ethanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcoholic beverages equivalent to 30g of alcohol per day for men and 20g/d for women for 3 weeks
Trial: NCT03060265
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administrating SALINE IV pre-cesarean section
Trial: NCT00133432
Drug: Zinc
RxNorm normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03116022
Drug: Estriol
RxNorm normalized name: Estriol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women using drug 1 mg / 1g in the proximal third of the vagina every other night for 12 weeks
Trial: NCT03116022
Drug: Distal estriol
RxNorm normalized name: Estriol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women using drug 1 mg / 1g at the distal third of the vagina every other night for 12 weeks
Trial: NCT03116022
Drug: Vaginal Gel
RxNorm normalized name: VAGINAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women using a base water gel lubricant during intercourse
Trial: NCT00909688
Drug: BLI-489
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00909688
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00237159
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01443026
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02202577
Drug: Chlorhexidine - Isopropyl alcohol
RxNorm normalized name: chlorhexidine / isopropyl alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied to skin pre-operatively for surgical site anti-sepsis; regulated as a drug by FDA
Trial: NCT01736150
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Starting dose of 1 tablet (800mg), three times per day (2.4g/day)with meals.~* If serum phosphorus is higher than 5.5 mg/dL on Visit 3, 4, or 5, then dose increased by one additional tablet (800 mg). Three times daily with meals.
Trial: NCT00000373
Drug: placebo + fluoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01177358
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1mL of normal saline in a placebo vial containing 2mL of normal saline will be injected along three sites (midline and 1.5cm lateral from midline) following a thyroidectomy or parathyroidectomy.
Trial: NCT00865215
Drug: INDERAL® LA 160 mg Capsules, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Wyeth Pharmaceuticals formulated products under fasting conditions
Trial: NCT01873508
Drug: RO4917523
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast release MR capsule, single dose
Trial: NCT01873508
Drug: RO4917523
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target release MR capsule, single dose
Trial: NCT01873508
Drug: RO4917523
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow release MR capsule, single dose
Trial: NCT01873508
Drug: RO4917523
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[13C\]-labeled tracer dose i.v.
Trial: NCT00494832
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 minutes loading dose of 0.9 mcg/kg~Maintenance dose of 0.6 mcg/kg/hour
Trial: NCT00744627
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine placebo-matching capsules
Trial: NCT02355119
Drug: FOLFOXIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 5-Fluorouracil/Folinic Acid, Irinotecan, Oxaliplatin
Trial: NCT04062838
Drug: Dextrose 50
RxNorm normalized name: DEXTROSE 50% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As above
Trial: NCT01802723
Drug: Drug: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03324854
Drug: Prophylactic
RxNorm normalized name: Caries prophylactic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotic 1gm of cefalotin was administered 30 minutes before the incisión.
Trial: NCT01743144
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline (NaCl 9%) is going to be used, an initial normal saline bolus dose 0.3ml/kg will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous normal saline infusion of 0.1 ml/kg/h. Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
Trial: NCT03063645
Drug: AC-1202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 g AC-1202 mixed in 240 mL of water at Hour 0 Day 1
Trial: NCT02121639
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02121639
Drug: AZD5363
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04479852
Drug: SP-624
RxNorm normalized name: SPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT04479852
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT01166646
Drug: Halobetasol Proprionate Lotion 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply 3.5 grams twice daily for 1-2 weeks
Trial: NCT01166646
Drug: Halobetasol Proprionate Cream 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply 3.5 grams twice daily for 1-2 weeks
Trial: NCT00265122
Drug: Placebo SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one SC injection each week for 4 weeks (Weeks 0-3 in Intervention Period 1 or Weeks 8-11 in Intervention Period 2 for Population 1 or at Weeks 0-3 in Intervention Period 1 for Population 2)
Trial: NCT00265122
Drug: Placebo IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one IV infusion over a period of not less than 2 hours at Week 0 in Intervention Period 1 for Population 1 and Population 2 or at Week 8 in Intervention Period 2 for Population 1
Trial: NCT03131479
Drug: LIK066
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIK066 50 mg tablets taken orally once daily before breakfast for 7 days.
Trial: NCT01417988
Drug: Experimental: Empiric TB treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiation of 4 drug TB treatment (8 weeks of 4 drug, 16 weeks of 2 drug therapy) followed by ART (efavirenz-based) within 2 weeks
Trial: NCT01417988
Drug: ART only arm
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ART (efavirenz-based) only (+ pyridoxine 50mg) given within 2 weeks after enrolment
Trial: NCT03141970
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone for 12 weeks as follows 30 mg/m2 on alternate days for 4 weeks 20 mg/m2 on alternate days for 4 weeks 10 mg/m2 on alternate days for 4 weeks
Trial: NCT01127204
Drug: AZT-3TC-LPV/r twice a day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZT sirup (10mg/ml): 4 mg/kg or 180 mg/m2 twice daily 3TC sirup (10mg/ml): 4 mg/kg twice daily LPV/r sirup (80/20 mg/ml): 12 mg/kg twice daily
Trial: NCT01127204
Drug: ABC-3TC-EFV once a day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABC sirup (20mg/ml): 16 mg/kg once daily in the morning 3TC sirup (10mg/ml): 8 mg/kg once daily in the morning EFV sirup (30mg/ml): 25 mg/kg once daily in the morning before food intake
Trial: NCT00323986
Drug: azithromycin (drug)
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00656643
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two subconjunctival injections of placebo.
Trial: NCT01166698
Drug: AZD9819
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled single doses of suspension via SPIRA nebuliser
Trial: NCT01166698
Drug: AZD9819
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled multiple doses of suspension via SPIRA nebuliser, once daily for 10 (maximum 14) days
Trial: NCT01166698
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled doses of suspension via SPIRA nebuliser given either as single (Part A) or multiple doses (Part B)
Trial: NCT05259098
Drug: Sufentanil Sublingual Tablet System
RxNorm normalized name: sufentanil Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil Sublingual Tablet System is a sublingual opioid patient controlled analgesia system. It was used for postoperative analgesia after surgery associated with moderate to severe pain.
Trial: NCT05259098
Drug: Intravenous Patient-Controlled Analgesia with morfine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Patient-Controlled Analgesia with morfine. It was used for postoperative analgesia after surgery associated with moderate to severe pain.
Trial: NCT03048825
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone 25 mg once daily
Trial: NCT03048825
Drug: Spironolactone-Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Spironolactone-Placebo once daily
Trial: NCT01323374
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, placebo TID
Trial: NCT01292993
Drug: 400 mg LX4211
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of LX4211 given as a solid oral dose form
Trial: NCT01724814
Drug: HM12460A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose SC administration ranging from 1.2 nmol/kg to 19.2 nmol/kg of HM12460A
Trial: NCT01724814
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Singe dose SC administration of Placebo
Trial: NCT00090675
Drug: ZD1839
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03092193
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 phenotyped for CYP2C9 and CYP2C19 (by PCR) and for the pharmacokinetics of naproxen, saliva samples will be collected of these patients at different times after ingestion of a tablet of naproxen (500mg) (before, 0,25; 0,5; 0,75; 1; 1,5; 2; 3; 4; 5; 6; 8; 11; 24; 48; 72 e 96 hours after ingestion).
Trial: NCT03092193
Drug: Naproxen-esomeprazole
RxNorm normalized name: Esomeprazole Magnesium/Naproxen 20 MG-500 MG Oral Tablet, Delayed Release [NAPROXEN-ESOMEPRAZOLE MAGNESIUM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 phenotyped for CYP2C9 and CYP2C19 (by PCR) and for the pharmacokinetics of naproxen-esomeprazole, saliva samples will be collected of these patients at different times after ingestion of a tablet of naproxen-esomeprazole (500mg+20mg) (after one month of the first collection) (before, 0,25; 0,5; 0,75; 1; 1,5; 2; 3; 4; 5; 6; 8; 11; 24; 48; 72 e 96 hours after ingestion).
Trial: NCT00773461
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv every 4 weeks for 24 weeks
Trial: NCT00190528
Drug: neoadjuvant chemotherapy + radical hysterectomy
RxNorm normalized name: Campsis radicans flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03683082
Drug: Sham O2 (medical air)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical air supplementation via Venturi mask
Trial: NCT04362644
Drug: PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants will undergo PET/CT with the glucose analogue \[F-18\]FDG and the translocator protein (TSPO) ligand \[F-18\]DPA-714 in two separate imaging sessions.
Trial: NCT00090064
Drug: Lactose placebo pill
RxNorm normalized name: lactose Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg followed by a supplemental half-dose of 62.5 mg
Trial: NCT04464733
Drug: HRS9950
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS9950
Trial: NCT04464733
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02531451
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02531451
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03060447
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets Administered orally
Trial: NCT03933787
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomised study: session 1 the volunteer will receive either saxagliptin or placebo. Session 2 the volunteer will receive the placebo or saxagliptin
Trial: NCT01564121
Drug: acid Zoledronic
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Treatment with zoledronic acid will be initiated during hospitalization, the day after the removal of redundant. Intravenous injection of 4 mg. of zoledronate diluted in sodium chloride 9 / 1000 or a solution of 5% dextrose in intravenous over 15 minutes. In the absence of intolerance clinic, an infusion of zoledronic acid in the same doses and modalities will be performed in a hospital (on the occasion of a follow-up visit after surgery) at the 3rd, 6th, 9th and 12th weeks after the first, or 5 injections. )
Trial: NCT00480597
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02113878
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor.
Trial: NCT01882374
Drug: TXA127
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection, 300mcg/kg/day for 28 days
Trial: NCT02803073
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone Cypionate Intramuscular injections will be administered weekly
Trial: NCT02803073
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline Intramuscular injections will be administered weekly
Trial: NCT01028339
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL/kg of 7.5% hypertonic saline associated to hydroxyethyl starch